Brief: Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results And Recent Portfolio Execution
29/10/2024 11:34
Oct 29 (Reuters) - Kiniksa Pharmaceuticals Ltd KNSA.O :
* KINIKSA PHARMACEUTICALS REPORTS THIRD QUARTER 2024
FINANCIAL
RESULTS AND RECENT PORTFOLIO EXECUTION
* KINIKSA PHARMACEUTICALS LTD: EXPECTS 2024 ARCALYST NET
PRODUCT
REVENUE OF BETWEEN $410 MILLION AND $420 MILLION
Source text: ID:nGNX4P9Kgk
Further company coverage: KNSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiniksa Pharmaceuticals International
See all newsKiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary
Kiniksa Pharmaceuticals Q2 product revenue rises on ARCALYST sales
Kiniksa Pharmaceuticals International, PLC expected to post earnings of 30 cents a share - Earnings Preview
Cardiovascular drugmaker Kiniksa's Q1 net income rises
Kiniksa Q4 revenue rises on ARCALYST sales